SCHEMBL6030149

SCHEMBL6030149

CCCCCCCCCCc1cc(C(=O)OC(C)(C)C)c(NC(=O)OCCc2ccccc2)s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.48
MAPT P10636 3/20 0.45
NPSR1 Q6W5P4 1/20 0.45
GAA P10253 3/20 0.44
CTSK P43235 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
GLS O94925 1/20 0.41
MGLL Q99685 1/20 0.40
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 3/20 0.40
CYP2C19 P33261 2/20 0.40
HTT P42858 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
RECQL P46063 1/20 0.39
RAB9A P51151 1/20 0.39
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6030453 0.95 HSD17B10 (0.47) HSD17B10MAPTNPSR1GAAGLS
SCHEMBL6030980 0.95 HSD17B10 (0.47) HSD17B10MAPTNPSR1GAAGLS
SCHEMBL6030240 0.95 HSD17B10 (0.47) HSD17B10MAPTNPSR1GAAGLS
SCHEMBL6031081 0.93 HSD17B10 (0.47) HSD17B10MAPTNPSR1GAACTSK
SCHEMBL6030894 0.92 GAA (0.48) HSD17B10MAPTNPSR1GAARXFP1
SCHEMBL6030052 0.91 HSD17B10 (0.50) HSD17B10MAPTNPSR1GAARXFP1
SCHEMBL6031643 0.91 HSD17B10 (0.49) HSD17B10MAPTNPSR1GAARXFP1
SCHEMBL6029945 0.89 HSD17B10 (0.55) HSD17B10MAPTGAARXFP1KDM4E
SCHEMBL6031371 0.89 HSD17B10 (0.55) HSD17B10MAPTGAARXFP1KDM4E
SCHEMBL6030817 0.89 HSD17B10 (0.55) HSD17B10MAPTGAARXFP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
EP-1467978-A4 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-11-02 EP disclosed
EP-1467978-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 EP disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed
WO-2003053944-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL HSD17B10 126/4885MAPT 4105/4885NPSR1 393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.